Components of clinical trials for vasovagal syncope

被引:20
作者
Sheldon, R [1 ]
Rose, S [1 ]
机构
[1] Univ Calgary, Hlth Sci Ctr, Fac Med, Cardiovasc Res Grp, Calgary, AB T2N 4N1, Canada
来源
EUROPACE | 2001年 / 3卷 / 03期
关键词
vasovagal syncope; tilt-table test; randomized clinical trials; quality of life; cost utility; drug therapy; pacemaker therapy;
D O I
10.1053/eupc.2001.0168
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The time is ripe for adequately powered, randomized, placebo-controlled clinical trials in vasovagal syncope. Vasovagal syncope is a common syndrome, the symptoms of which can be troublesomely frequent. Ii is usually diagnosed by tilt-table testing, although this has persistent problems with both sensitivity and specificity. patients with syncope and positive tilt tests have been the subjects of numerous studies of natural history, risk stratification, and treatment. This payer discusses studies of treatments for vasovagal syncope in the context of a classification of the levels of evidence that can be gleaned from clinical studies. The reasons for placebo-controlled trials al e reviewed, as is the evidence for various methods of risk stratification. Data for power calculations are presented for the primary outcome, the time to the first syncope recurrence. Strengths and weakness of the four main types of outcomes for clinical trials are compared. (C) 2001 The European Society of Cardiology.
引用
收藏
页码:233 / 240
页数:8
相关论文
共 50 条
  • [41] Vasovagal syncope and Darwinian fitness
    Rolf R. Diehl
    Clinical Autonomic Research, 2005, 15 : 126 - 129
  • [42] Genetic markers of vasovagal syncope
    Sheldon, Robert S.
    Gerull, Brenda
    AUTONOMIC NEUROSCIENCE-BASIC & CLINICAL, 2021, 235
  • [43] Pacing in vasovagal syncope: Physiology, pacemaker sensors, and recent clinical trials-Precise patient selection and measurable benefit
    Sutton, Richard
    de Jong, Jelle S. Y.
    Stewart, Julian M.
    Fedorowski, Artur
    de Lange, Frederik J.
    HEART RHYTHM, 2020, 17 (05) : 821 - 828
  • [44] Diagnosis and treatment of vasovagal syncope
    Evrengül, H
    Evrengül, H
    Zungur, M
    Tanriverdi, H
    NEUROLOGIA CROATICA, 2005, 54 (1-2): : 5 - 18
  • [45] Treatment of vasovagal syncope: An update
    Armaganijan L.
    Morillo C.A.
    Current Treatment Options in Cardiovascular Medicine, 2010, 12 (5) : 472 - 488
  • [46] Management strategies for vasovagal syncope
    Ali, Muzaffar
    Pachon Maetos, Jose Carlos
    Kichloo, Asim
    Masudi, Sundas
    Grubb, Blair P.
    Kanjwal, Khalil
    PACE-PACING AND CLINICAL ELECTROPHYSIOLOGY, 2021, 44 (12): : 2100 - 2108
  • [47] Atomoxetine for suppression of vasovagal syncope
    Robert S. Sheldon
    Colette Seifer
    Ratika Parkash
    Roopinder K. Sandhu
    Rasha Hamzeh
    Satish R. Raj
    Clinical Autonomic Research, 2023, 33 : 23 - 28
  • [48] Familial predisposition to vasovagal syncope
    Negrusz-Kawecka, Marta
    Bankowski, Tomasz
    Tarin, Mateusz
    Paprocka, Magdalena
    Mercik, Agnieszka
    Misztal, Jowita
    Nowak, Piotr
    Zysko, Dorota
    Gajek, Jacek
    ACTA CARDIOLOGICA, 2012, 67 (03) : 279 - 284
  • [49] Vasovagal syncope and Darwinian fitness
    Diehl, RR
    CLINICAL AUTONOMIC RESEARCH, 2005, 15 (02) : 126 - 129
  • [50] Neurohormones in Vasovagal Syncope: Are They Important?
    Williford, Noah N.
    Chapleau, Mark W.
    Olshansky, Brian
    JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2019, 8 (12):